FabI inhibitors (GlaxoSmithKline/Medicines for Malaria Venture)
N/A
Report date: 2025/03/20 16:05:17
NME
Base Information
Drug NameFabI inhibitors (GlaxoSmithKline/Medicines for Malaria Venture)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcMedicines for Malaria Venture
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A